EQS-News: RHÖN-KLINIKUM AG holds steady course in first quarter of 2025 – outlook confirmed
|
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Quarter Results/Quarter Results
Corporate News
RHÖN-KLINIKUM AG, one of the largest healthcare providers in Germany, has started into financial year 2025 as expected. From January to March 2025 a total of 240,137 patients were treated in the Group’s hospitals and medical care centres on an outpatient and inpatient basis (Q1 2024: 234,151). Revenue increased by 8.3% to EUR 414.7 million (Q1 2024: EUR 382.8 million). Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to EUR 22.6 million (Q1 2024: EUR 25.2 million). Taking into account the depreciation/amortisation, financing costs and taxes, EBITDA resulted in a consolidated profit of EUR 7.3 million (Q1 2024: EUR 11.1 million). This decrease was primarily driven by the end of funds paid out by the legislator for higher energy expenses and the declining trend in interest rates. “We are operating in a challenging environment and have made a good start into financial year 2025. With our strategic position and close collaboration within the Asklepios Group, Dr. Gunther K. Weiß, member of the Board of Management of RHÖN-KLINIKUM AG, added: “At our five hospital sites of Campus Frankfurt (Oder), Zentralklinik Bad Berka, Campus Bad Neustadt and the university hospitals in Giessen and Marburg, our highly qualified and dedicated employees offer the entire range of modern outpatient and inpatient hospital care, from basic care delivered close to where patients live to highly specialised university medical care. In this way, we ensure that our patients always receive the treatment that is best fit to their needs.”
For the current financial year, we expect revenues of EUR 1.7 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect This forecast reflects the heightened regulatory interference by the German legislator and the political implementation of the necessary hospital reform. We note that our outlook is subject to considerable uncertainties in connection with the numerous global crises that are resulting among other things in higher prices and supply chain issues, as well as any further regulatory measures impacting our remuneration structure for medical services in 2025.
RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 913,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,700 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
Contact: RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale
08.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | RHÖN-KLINIKUM Aktiengesellschaft |
| Salzburger Leite 1 | |
| 97616 Bad Neustadt a. d. Saale | |
| Germany | |
| Phone: | +49 (0)9771 - 65-0 |
| Fax: | +49 (0)9771 - 97 467 |
| E-mail: | rka@rhoen-klinikum-ag.com |
| Internet: | www.rhoen-klinikum-ag.com |
| ISIN: | DE0007042301 |
| WKN: | 704230 |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2132736 |
| End of News | EQS News Service |
|
|
2132736 08.05.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 1.360,16 | 1.402,01 | 1.446,09 | 1.463,98 | 1.595,62 | 1.700,00 | 0,00 | |
| EBITDA1,2 | 80,23 | 101,16 | 105,65 | 105,88 | 110,77 | 103,00 | 0,00 | |
| EBITDA-Margin3 | 5,90 | 7,22 | 7,31 | 7,23 | 6,94 | 6,06 | 0,00 | |
| EBIT1,4 | 10,60 | 30,52 | 36,11 | 40,40 | 48,15 | 42,00 | 0,00 | |
| EBIT-Margin5 | 0,78 | 2,18 | 2,50 | 2,76 | 3,02 | 2,47 | 0,00 | |
| Net Profit (Loss)1 | 2,46 | 30,23 | 26,94 | 40,17 | 45,21 | 38,00 | 0,00 | |
| Net-Margin6 | 0,18 | 2,16 | 1,86 | 2,74 | 2,83 | 2,24 | 0,00 | |
| Cashflow1,7 | 113,30 | 97,50 | 41,30 | 109,00 | 127,60 | 110,00 | 0,00 | |
| Earnings per share8 | 0,02 | 0,42 | 0,38 | 0,58 | 0,65 | 0,56 | 0,70 | |
| Dividend per share8 | 0,00 | 0,00 | 0,15 | 0,00 | 0,10 | 0,10 | 0,15 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Rhön-Klinikum | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 704230 | DE0007042301 | AG | 883,91 Mio € | 19.06.1991 | Halten | 9F2G86FM+GX |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 16,92 | 26,47 | 0,64 | 23,91 | 0,69 | 6,93 | 0,55 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,10 | 0,10 | 0,76% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 27.05.2026 | 07.05.2026 | 06.08.2026 | 05.11.2026 | 26.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +4,97% | +6,16% | +3,94% | -10,20% | +428,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
